ABT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 84.1% compared to Abbott Laboratories's net margin of 12.41%. Abbott Laboratories's return on equity of 32.63% beat Boston Scientific's return on equity of 8.96%.

Abbott Laboratories has a consensus price target of $136.47, signalling upside risk potential of 10.1%. On the other hand Boston Scientific has an analysts' consensus of $115.37 which suggests that it could grow by 27.28%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.81%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Boston Scientific quarterly revenues of $4.6B. Abbott Laboratories's net income of $9.2B is higher than Boston Scientific's net income of $566M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.20x while Boston Scientific's PE ratio is 72.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.16x versus 8.04x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 84.1% compared to Abbott Laboratories's net margin of 28.41%. Abbott Laboratories's return on equity of 32.63% beat Intuitive Surgical's return on equity of 15.6%.

Abbott Laboratories has a consensus price target of $136.47, signalling upside risk potential of 10.1%. On the other hand Intuitive Surgical has an analysts' consensus of $619.74 which suggests that it could grow by 35.42%. Given that Intuitive Surgical has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.81%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Abbott Laboratories's net income of $9.2B is higher than Intuitive Surgical's net income of $685.7M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.20x while Intuitive Surgical's PE ratio is 71.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.16x versus 19.83x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 84.1% compared to Abbott Laboratories's net margin of 26.88%. Abbott Laboratories's return on equity of 32.63% beat ResMed's return on equity of 25.56%.

Abbott Laboratories has a consensus price target of $136.47, signalling upside risk potential of 10.1%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 31.72%. Given that ResMed has higher upside potential than Abbott Laboratories, analysts believe ResMed is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.81%. ResMed offers a yield of 1.01% to investors and pays a quarterly dividend of $0.53 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than ResMed quarterly revenues of $1.3B. Abbott Laboratories's net income of $9.2B is higher than ResMed's net income of $344.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.20x while ResMed's PE ratio is 24.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.16x versus 6.12x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 84.1% compared to Abbott Laboratories's net margin of 8.48%. Abbott Laboratories's return on equity of 32.63% beat Stryker's return on equity of 15.22%.

Abbott Laboratories has a consensus price target of $136.47, signalling upside risk potential of 10.1%. On the other hand Stryker has an analysts' consensus of $423.15 which suggests that it could grow by 25.43%. Given that Stryker has higher upside potential than Abbott Laboratories, analysts believe Stryker is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.81%. Stryker offers a yield of 0.97% to investors and pays a quarterly dividend of $0.84 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Stryker quarterly revenues of $6.4B. Abbott Laboratories's net income of $9.2B is higher than Stryker's net income of $546M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.20x while Stryker's PE ratio is 43.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.16x versus 5.76x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.